Revolution Medicines’ CDO Sandler sells $1.2m in stock
What it means
- What to watch: The headline hangs on one number ($1) — one data point is a snapshot, so the trailing trend is the context it needs.
- How the stock is trading: $RVMD +9.97% in the latest session.
- Timing: Filed after the close: the price beside it finished its day before the story existed, so the next session gets the first real vote.
Where the stock stands
$RVMD last traded at $213.60, +9.97% on the session. That puts it 4.8% shy of its 52-week high of $224.31 and 268% clear of its low of $58.00 — within a tenth of its 52-week high. Over the year it has ranged 287% from low to high: a very wide band; big swings are routine for this one, not news. These are latest-session quotes, not live prices — the live tape is on the $RVMD page.
How much coverage it is getting
This is the only story Wook has logged on $RVMD in the last 30 days — a quiet name that just got a headline. 12 related stories from the same name or desk are listed beside this one.
The bigger picture
Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. On Wook's supply-chain scanner, Health Care reads calm today — no unusual stress in the filings and disclosures it watches. The scanner equivalent of a quiet night shift.
Coming up
$RVMD earnings today. These were on the calendar before this story and are not caused by it, but the nearest is close enough that the hard numbers get the last word soon.
What to watch next
The $RVMD page has the full chart, the filings and the valuation model behind every figure here. Comparing how two or three outlets frame the same story is the fastest way to separate the facts from the angle. Wook AI, above, can pull live figures and run the numbers on request — how far $RVMD is from its high, or how this week's coverage compares.
How this analysis was made
Investing.com published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $RVMD. It carried $1.2 million, shown as published and not recalculated. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on October 1, 2026. $RVMD has moved +3.37% ($206.64 to $213.60). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.